Skip to Content

Daiichi Sankyo Co Ltd

4568: XTKS (JPN)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
¥‎2,833.00KmywbmHngghktbnf

Daiichi Sankyo's World-Leading Antibody Drug Conjugate Platform Continues to Make Progress

Business Strategy and Outlook

Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long history, it also has numerous lucrative business lines including generics, anticoagulants, painkillers, and heart medications. In 2019 it formed a partnership with AstraZeneca and will co-develop and co-commercialize Enhertu and Dato-DXd, its two leading assets from its ADC platform. In 2023, it formed another partnership with Merck & Co. to co-develop and co-commercialize three other ADCs: HER3-DXd (HER3 ADC), I-DXd (B7-H3 ADC), and R-DXd (CDH6 ADC). We expect its ADC platform and other pipeline assets to drive growth over the next 10 years.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of 4568 so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center